临床试验:早期疾病清除与长期结局的关联——乌司奴单抗治疗溃疡性结肠炎3期UNIFI研究的4年结果
UNIFI项目评估乌司奴单抗诱导后8周疾病清除(同时症状缓解和组织内镜下黏膜改善)与长期结局的关联。诱导后8周疾病清除率在安慰剂组为5.9%,乌司奴单抗130 mg组为15.2%,约6 mg/kg组为15.1%。达到疾病清除的诱导应答者接受乌司奴单抗维持治疗至第44周和第200周时,临床、症状和生活质量缓解率更高。
要点
- 诱导后8周疾病清除率:安慰剂组5.9%,乌司奴单抗130 mg组15.2%,约6 mg/kg组15.1%。
- 诱导应答者中,达到疾病清除者第44周临床缓解率63.6%,未达到者为35.2%(名义p<0.001)。
- 达到疾病清除者第200周症状缓解率73.4%,仅有症状缓解无HEMI者为53.5%(名义p=0.002),两者均无者为45.1%(名义p<0.001)。
核心结论
- 乌司奴单抗诱导后8周达到疾病清除的患者,接受乌司奴单抗维持治疗时更可能获得长期临床、症状和生活质量缓解。
研究设计与样本
- UNIFI为3期项目,包括随机、安慰剂对照的诱导和维持研究及长期扩展研究,评估静脉乌司奴单抗诱导(130 mg或约6 mg/kg)和皮下乌司奴单抗维持治疗(90 mg每8周或每12周)至4年,纳入溃疡性结肠炎患者。
主要发现
- 诱导后8周疾病清除率:安慰剂组5.9%,乌司奴单抗130 mg组15.2%,约6 mg/kg组15.1%。
- 乌司奴单抗诱导应答者随机接受乌司奴单抗维持治疗,达到与未达到8周疾病清除者第44周临床缓解率分别为63.6%和35.2%(名义p<0.001)。
- 达到疾病清除、仅有症状缓解无HEMI、两者均无的诱导应答者第200周症状缓解率分别为73.4%、53.5%(名义p=0.002)、45.1%(名义p<0.001)。
- 上述三组第200周炎症性肠病问卷缓解(评分≥170)率分别为58.2%、46.5%(名义p=0.09)、42.7%(名义p=0.05)。
关键数值与推荐
- 临床缓解定义为Mayo评分≤2且无单项子评分>1。
- 症状缓解定义为Mayo排便频率子评分0/1且直肠出血子评分0。
- 炎症性肠病问卷缓解定义为评分≥170。
- 疾病清除定义为同时症状缓解和组织内镜下黏膜改善(HEMI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Achievement of disease clearance (simultaneous symptomatic remission and histo-endoscopic mucosal improvement [HEMI]) following induction therapy may lead to better long-term outcomes in ulcerative colitis (UC). AIM: To evaluate disease clearance in the phase 3 UNIFI program and its association with long-term outcomes. METHODS: UNIFI comprised randomised, placebo-controlled induction and maintenance studies and a long-term extension, which evaluated intravenous ustekinumab induction (130 mg or ~6 mg/kg) and subcutaneous ustekinumab maintenance therapy (90 mg every 8 or 12 weeks) through 4 years in patients with UC. RESULTS: Disease clearance was achieved by 5.9%, 15.2% and 15.1% of patients 8 weeks after placebo or ustekinumab 130 mg or ~6 mg/kg induction, respectively. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who did or did not achieve disease clearance 8 weeks after induction, 63.6% and 35.2% (nominal p < 0.001), respectively, achieved clinical remission (Mayo score ≤ 2, no individual subscore > 1) at Week 44. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who achieved disease clearance, symptomatic remission without HEMI, or neither symptomatic remission nor HEMI 8 weeks after induction, 73.4%, 53.5% (nominal p = 0.002) and 45.1% (nominal p < 0.001), respectively, achieved symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and 58.2%, 46.5% (nominal p = 0.09) and 42.7% (nominal p = 0.05), respectively, achieved Inflammatory Bowel Disease Questionnaire remission (score ≥ 170) at Week 200. CONCLUSIONS: Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. TRIAL REGISTRATION: NCT02407236.
引用
- Danese S, Leong RW, Sands BE, et al. Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Aliment Pharmacol Ther. 2025. PMID: 40668079. doi:10.1111/apt.70264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。